Octagon Capital Advisors as of June 30, 2026
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 27 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 16.1 | $180M | 1.8M | 97.48 | |
| Definium Therapeutics Com Shs (DFTX) | 12.5 | $139M | 3.0M | 47.04 | |
| Abivax Sa Sponsored Ads (ABVX) | 11.9 | $132M | 993k | 133.26 | |
| Cogent Biosciences (COGT) | 8.2 | $91M | 2.4M | 38.70 | |
| Alumis (ALMS) | 7.2 | $80M | 2.8M | 28.14 | |
| Arrivent Biopharma (AVBP) | 6.2 | $69M | 2.0M | 34.74 | |
| Taysha Gene Therapies Com Shs (TSHA) | 5.9 | $66M | 9.7M | 6.81 | |
| Bioage Labs (BIOA) | 3.9 | $43M | 1.7M | 24.51 | |
| Mirum Pharmaceuticals (MIRM) | 3.6 | $40M | 339k | 117.07 | |
| Kymera Therapeutics (KYMR) | 3.2 | $36M | 310k | 114.67 | |
| Aktis Oncology (AKTS) | 2.8 | $31M | 961k | 32.23 | |
| Xenon Pharmaceuticals (XENE) | 2.7 | $30M | 490k | 60.36 | |
| Erasca Call Call Option | 2.1 | $23M | 1.3M | 18.32 | |
| Palisade Bio (PALI) | 1.9 | $22M | 10M | 2.09 | |
| Ocular Therapeutix (OCUL) | 1.8 | $20M | 2.1M | 9.82 | |
| Disc Medicine (IRON) | 1.8 | $20M | 270k | 73.14 | |
| Summit Therapeutics (SMMT) | 1.6 | $18M | 1.3M | 14.57 | |
| Pharvaris N V (PHVS) | 1.4 | $16M | 457k | 34.58 | |
| Adlai Nortye Sponsored Ads (ANL) | 1.0 | $11M | 935k | 11.50 | |
| Precision Biosciences Com New (DTIL) | 1.0 | $11M | 1.4M | 7.86 | |
| Dbv Technologies S A Sponsored Ads (DBVT) | 0.8 | $9.4M | 574k | 16.40 | |
| Faeth Therapeutics Com New (FTH) | 0.8 | $9.0M | 361k | 25.00 | |
| Gyre Therapeutics Incorporated (GYRE) | 0.6 | $6.3M | 954k | 6.59 | |
| Trevi Therapeutics (TRVI) | 0.5 | $5.9M | 315k | 18.65 | |
| Unicycive Therapeutics Com New (UNCY) | 0.4 | $4.7M | 1.0M | 4.69 | |
| Context Therapeutics (CNTX) | 0.2 | $1.7M | 3.1M | 0.55 | |
| Gossamer Bio (GOSS) | 0.1 | $1.3M | 7.8M | 0.16 |
